GCAVX Performance — GMO U.S. Small Cap Value Fund, Class VI
Data updated: 2026-09-29
GCAVX returned +14.39% year to date and +39.04% over one year to May 2026. Annualised returns are +22.32% over 3 years and +9.95% over 5 years. The fund beat its US Small Blend category average: $100 invested three years ago grew to $183, against $160 for the category, and to $139 over one year, against $132. Volatility over the past three years was 19.52% a year. In the 12 months to May 2026 the fund lost a net $1.3M, and assets reached $45.29M.
GCAVX Growth of $100
What $100 invested in GMO U.S. Small Cap Value Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the US Small Blend category average over the same months.
| Period | GCAVX | Category average |
|---|---|---|
| 1 year (Jun 2025 – May 2026) | $139 | $132 |
| 3 years (Jun 2023 – May 2026) | $183 | $160 |
| 5 years (Jun 2021 – May 2026) | $161 | $135 |
| Since data start (Sep 2019 – May 2026) | $244 | $206 |
GCAVX Trailing Returns
Total returns to May 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +14.39% |
| 1 year | +39.04% |
| 3 years (annualised) | +22.32% |
| 5 years (annualised) | +9.95% |
GCAVX Annual Returns
Calendar-year total returns of GMO U.S. Small Cap Value Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–May) | +14.39% |
| 2025 | +15.25% |
| 2024 | +11.17% |
| 2023 | +22.72% |
| 2022 | −14.02% |
| 2021 | +35.70% |
| 2020 | +2.39% |
| 2019 (Sep–Dec) | +13.42% |
GCAVX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +5.6% | +1.0% | −3.4% | +10.6% | +0.3% | — | — | — | — | — | — | — |
| 2025 | +3.3% | −4.9% | −5.8% | −4.6% | +7.4% | +3.3% | +1.1% | +9.0% | +2.5% | −0.4% | +3.0% | +1.4% |
| 2024 | −2.9% | +3.2% | +5.0% | −6.2% | +5.9% | −2.6% | +11.9% | −1.5% | −0.4% | −1.6% | +9.4% | −7.7% |
| 2023 | +10.6% | −1.8% | −4.2% | −3.0% | −2.6% | +10.8% | +5.9% | −3.7% | −3.1% | −5.4% | +8.0% | +11.6% |
| 2022 | −4.3% | +0.4% | −1.8% | −5.5% | +3.2% | −11.2% | +10.8% | −4.2% | −11.4% | +13.0% | +5.1% | −5.7% |
| 2021 | +3.4% | +11.4% | +7.6% | +1.8% | +3.5% | −1.9% | −2.4% | +2.0% | −1.7% | +3.2% | −0.6% | +5.4% |
| 2020 | −5.2% | −11.5% | −26.1% | +15.2% | +4.1% | +2.6% | +3.5% | +5.8% | −3.6% | +1.9% | +16.9% | +6.9% |
| 2019 | — | — | — | — | — | — | — | — | +4.8% | +2.9% | +2.8% | +2.4% |
GCAVX Risk
Risk measures from monthly returns over Jun 2023 – May 2026.
- 3-year volatility (annualised): 19.52%
- 3-year Sharpe ratio: 0.91 (vs 4.5% risk-free rate)
- Best month: +11.95% (Jul 2024)
- Worst month: −7.72% (Dec 2024)
GCAVX Fund Flows
Monthly money in and out of GMO U.S. Small Cap Value Fund, from SEC Form N-PORT.
- 12-month net flow: −$1.3M
- 12-month gross sales (incl. reinvestments): $3.6M
- Sales ÷ redemptions: 0.74×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| May 2026 | $0 | $1.2M | −$1.2M |
| Apr 2026 | $875K | $770K | $105K |
| Mar 2026 | $150K | $488K | −$338K |
| Feb 2026 | $350K | $0 | $350K |
| Jan 2026 | $0 | $0 | $0 |
| Dec 2025 | $2.2M | $1.1M | $1.0M |
| Nov 2025 | $0 | $900K | −$900K |
| Oct 2025 | $0 | $405K | −$405K |
| Sep 2025 | $0 | $0 | $0 |
| Aug 2025 | $0 | $0 | $0 |
| Jul 2025 | $81K | $0 | $81K |
| Jun 2025 | $0 | $0 | $0 |
GCAVX Assets Under Management
Net assets of GMO U.S. Small Cap Value Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-05-31 | $45.29M |
| 2026-02-28 | $43.52M |
| 2025-11-30 | $39.93M |
| 2025-08-31 | $39.21M |
| 2025-05-31 | $34.44M |
| 2025-02-28 | $35.47M |
| 2024-11-30 | $39.30M |
| 2024-08-31 | $40.98M |
| 2024-05-31 | $39.17M |
| 2024-02-29 | $34.84M |
| 2023-11-30 | $31.08M |
| 2023-08-31 | $31.21M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.